title: Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report.
authors.forename: Melih O
authors.initials: MO
authors.lastname: Babaoglu
authors.forename: Omer
authors.initials: O
authors.lastname: Karadag
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Saikawa
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Tamer
authors.initials: T
authors.lastname: Elkiran
authors.forename: Umit
authors.initials: U
authors.lastname: Yasar
authors.forename: Atila
authors.initials: A
authors.lastname: Bozkurt
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D004176:Dipyridamole / Q000009:adverse effects*; D004347:Drug Interactions; D017809:Fatal Outcome; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D010975:Platelet Aggregation Inhibitors; D003561:Cytarabine; D004176:Dipyridamole